261 related articles for article (PubMed ID: 28529576)
21. [Relationship between EGFR Promoter Region Methylation and Secondary Resistance Which may be Induced by Gefitinib].
Wang Q; Li M; Hu C
Zhongguo Fei Ai Za Zhi; 2015 Apr; 18(4):193-8. PubMed ID: 25936882
[TBL] [Abstract][Full Text] [Related]
22. Apatinib preferentially inhibits PC9 gefitinib-resistant cancer cells by inducing cell cycle arrest and inhibiting VEGFR signaling pathway.
Song YA; Ma T; Zhang XY; Cheng XS; Olajuyin AM; Sun ZF; Zhang XJ
Cancer Cell Int; 2019; 19():117. PubMed ID: 31073278
[TBL] [Abstract][Full Text] [Related]
23. [Drug resistance mechanism of non small cell lung cancer PC9/AB2 cell line with acquired drug resistance to gefitinib].
Ju LX; Zhou CC; Tang L; Zhao YM; Yang XJ; Su B; Meng SY; Li W; Yan LH; Ding YM
Zhonghua Jie He He Hu Xi Za Zhi; 2010 May; 33(5):354-8. PubMed ID: 20646614
[TBL] [Abstract][Full Text] [Related]
24. Sensitization of Non-Small Cell Lung Cancer Cells to Gefitinib and Reversal of Epithelial-Mesenchymal Transition by Aloe-Emodin
Peng M; Zheng Z; Chen S; Fang L; Feng R; Zhang L; Tang Q; Liu X
Front Oncol; 2022; 12():908031. PubMed ID: 35677158
[TBL] [Abstract][Full Text] [Related]
25. Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation.
Noro R; Gemma A; Kosaihira S; Kokubo Y; Chen M; Seike M; Kataoka K; Matsuda K; Okano T; Minegishi Y; Yoshimura A; Kudoh S
BMC Cancer; 2006 Dec; 6():277. PubMed ID: 17150102
[TBL] [Abstract][Full Text] [Related]
26. N-cadherin expression is a potential survival mechanism of gefitinib-resistant lung cancer cells.
Yamauchi M; Yoshino I; Yamaguchi R; Shimamura T; Nagasaki M; Imoto S; Niida A; Koizumi F; Kohno T; Yokota J; Miyano S; Gotoh N
Am J Cancer Res; 2011; 1(7):823-33. PubMed ID: 22016830
[TBL] [Abstract][Full Text] [Related]
27. Microarray expression profile of long non-coding RNAs in EGFR-TKIs resistance of human non-small cell lung cancer.
Cheng N; Li X; Zhao C; Ren S; Chen X; Cai W; Zhao M; Zhang Y; Li J; Wang Q; Zhou C
Oncol Rep; 2015 Feb; 33(2):833-9. PubMed ID: 25482516
[TBL] [Abstract][Full Text] [Related]
28. Overexpression of CTEN is associated with gefitinib resistance in non-small cell lung cancer.
Lu X; Zhang Y; Pan Y; Cao M; Zhou X; Zhang T
Oncol Lett; 2021 Jan; 21(1):40. PubMed ID: 33262832
[TBL] [Abstract][Full Text] [Related]
29. Estrogen receptor β1 activation accelerates resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in non-small cell lung cancer.
Fu S; Liu C; Huang Q; Fan S; Tang H; Fu X; Ai B; Liao Y; Chu Q
Oncol Rep; 2018 Mar; 39(3):1313-1321. PubMed ID: 29328407
[TBL] [Abstract][Full Text] [Related]
30. AC-93253 iodide, a novel Src inhibitor, suppresses NSCLC progression by modulating multiple Src-related signaling pathways.
Lai YH; Lin SY; Wu YS; Chen HW; Chen JJW
J Hematol Oncol; 2017 Nov; 10(1):172. PubMed ID: 29132432
[TBL] [Abstract][Full Text] [Related]
31. Oct4 plays a crucial role in the maintenance of gefitinib-resistant lung cancer stem cells.
Kobayashi I; Takahashi F; Nurwidya F; Nara T; Hashimoto M; Murakami A; Yagishita S; Tajima K; Hidayat M; Shimada N; Suina K; Yoshioka Y; Sasaki S; Moriyama M; Moriyama H; Takahashi K
Biochem Biophys Res Commun; 2016 Apr; 473(1):125-132. PubMed ID: 26996130
[TBL] [Abstract][Full Text] [Related]
32. γ Secretase inhibitor BMS-708163 reverses resistance to EGFR inhibitor via the PI3K/Akt pathway in lung cancer.
Xie M; He J; He C; Wei S
J Cell Biochem; 2015 Jun; 116(6):1019-27. PubMed ID: 25561332
[TBL] [Abstract][Full Text] [Related]
33. β-Elemene Reverses Gefitinib Resistance in NSCLC Cells by Inhibiting lncRNA H19-Mediated Autophagy.
Zhang R; Zheng Y; Zhu Q; Gu X; Xiang B; Gu X; Xie T; Sui X
Pharmaceuticals (Basel); 2024 May; 17(5):. PubMed ID: 38794196
[TBL] [Abstract][Full Text] [Related]
34. ANGPTL4 Regulates Lung Adenocarcinoma Pyroptosis and Apoptosis via NLRP3\ASC\Caspase 8 Signaling Pathway to Promote Resistance to Gefitinib.
Fang Y; Li X; Cheng H; Zhang L; Hao J
J Oncol; 2022; 2022():3623570. PubMed ID: 36467503
[TBL] [Abstract][Full Text] [Related]
35. Polyphyllin II Restores Sensitization of the Resistance of PC-9/ZD Cells to Gefitinib by a Negative Regulation of the PI3K/Akt/mTOR Signaling Pathway.
Zheng R; Jiang H; Li J; Liu X; Xu H
Curr Cancer Drug Targets; 2017; 17(4):376-385. PubMed ID: 28093061
[TBL] [Abstract][Full Text] [Related]
36. Activation of the FGF2-FGFR1 autocrine pathway: a novel mechanism of acquired resistance to gefitinib in NSCLC.
Terai H; Soejima K; Yasuda H; Nakayama S; Hamamoto J; Arai D; Ishioka K; Ohgino K; Ikemura S; Sato T; Yoda S; Satomi R; Naoki K; Betsuyaku T
Mol Cancer Res; 2013 Jul; 11(7):759-67. PubMed ID: 23536707
[TBL] [Abstract][Full Text] [Related]
37. Cyclooxygenase-2 mediates gefitinib resistance in non-small cell lung cancer through the EGFR/PI3K/AKT axis.
Deng QF; Fang QY; Ji XX; Zhou SW
J Cancer; 2020; 11(12):3667-3674. PubMed ID: 32284763
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of miR-23a increases the sensitivity of lung cancer stem cells to erlotinib through PTEN/PI3K/Akt pathway.
Han Z; Zhou X; Li S; Qin Y; Chen Y; Liu H
Oncol Rep; 2017 Nov; 38(5):3064-3070. PubMed ID: 28901474
[TBL] [Abstract][Full Text] [Related]
39. Targeting c-kit inhibits gefitinib resistant NSCLC cell growth and invasion through attenuations of stemness, EMT and acquired resistance.
Zhou Y; Wang L; Sun Z; Zhang J; Wang X
Am J Cancer Res; 2020; 10(12):4251-4265. PubMed ID: 33414998
[TBL] [Abstract][Full Text] [Related]
40. Akt/mTOR and AMPK signaling pathways are responsible for liver X receptor agonist GW3965-enhanced gefitinib sensitivity in non-small cell lung cancer cell lines.
Wang Q; Shen B; Qin X; Liu S; Feng J
Transl Cancer Res; 2019 Feb; 8(1):66-76. PubMed ID: 35116735
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
